This technology is a live poxvirus vaccine platform engineered so that the virus can multiply only when the antibiotic tetracycline is present. It is designed to pair the strong immune response of live poxvirus vaccines with a built-in on/off safety control, and it can carry antigens from other pathogens.
Description
Unmet Need - Current mpox vaccines either require multiple injections or are fully replication-competent with notable side effects. This technology adds a drug-controlled replication switch that can be used to limit viral replication.
The platform adds a small genetic “switch” to a live vaccinia virus. The switch controls a gene the virus needs to assemble new infectious particles. Without tetracycline, a repressor protein blocks that gene and the virus cannot complete replication. When tetracycline or doxycycline is supplied, the block is lifted and the virus replicates normally.
Because such switches can be “leaky” and let a little replication through, the design places a protective DNA element, called an insulator, next to the control region to help keep the gene tightly off. Insulators described include a sea urchin–derived sequence and a fluorescent marker gene. The same cassette can carry a gene for a foreign antigen, such as the Ebola glycoprotein, to create a dual-purpose vaccine. Delivery options include skin scarification, intradermal administration, and dissolvable microneedle arrays that can also carry tetracycline.
Applications
- Mpox vaccines with controllable replication
- Dual-target vaccines against mpox and Ebola
- Vaccinia-based vector vaccines for other pathogenic antigens
- Needle-free or minimally invasive delivery kits and microneedle patches
- Biodefense and stockpile vaccines against orthopoxviruses
Advantages
- Replication is controlled by tetracycline or doxycycline
- Added insulator element reduces unwanted gene activation
- Cassette can carry foreign antigens, enabling multi-pathogen vaccines
- Compatible with a lyophilized (freeze-dried) format and with scarification or microneedle delivery
- Built on the ACAM2000 vaccinia strain backbone
Invention Readiness
Tetracycline-dependent vaccinia constructs have been generated and characterized in cell culture. In the absence of doxycycline, no plaques formed for the lead construct (AGAM2024) or for an Ebola glycoprotein–expressing version, while normal plaques formed when doxycycline was present. The Ebola glycoprotein construct also showed surface expression of the antigen in infected cells.
IP Status
https://patents.google.com/patent/WO2026163096A1